Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    A new Locations section includes California as a study site, replacing the prior California Locations entry; the footer now shows revision v3.3.3 and the HHS Vulnerability Disclosure item has been removed.
    Difference
    0.2%
    Check dated 2025-12-23T14:18:53.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Results posted for NCT03007732 on 2025-12-05, with updated Cohort 2 endpoints and expanded safety and efficacy descriptions. The update also includes links to the study protocol and statistical analysis plan.
    Difference
    3%
    Check dated 2025-12-09T00:44:38.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page revision was updated to v3.3.2 and v3.2.0 was removed, with no changes to substantive study details. The update affects only the page version metadata. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T21:53:32.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Results Submitted is now listed as a status on the page. The previous No Results Posted notice has been removed, indicating a change in the results availability status.
    Difference
    0.4%
    Check dated 2025-11-17T20:07:32.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Administrative update to the study record reflecting a new last update date; no changes to the interventions, eligibility criteria, primary or secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T13:50:08.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Major update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.
    Difference
    2%
    Check dated 2025-10-06T04:23:30.000Z thumbnail image

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.